ClinicalTrials.gg
TerminatedNCT00174187Updated Dec 4, 2012Results posted

Treatment With Recombinant Human Growth Hormone (GH) in Children With Short Stature Secondary to a Long Term Corticoid Therapy

A Phase 3 interventional study of Somatropin in Endocrine System Diseases, sponsored by Pfizer. Terminated at 2 sites in France. Open to participants aged 11 Years to 17 Years. Per ClinicalTrials.gov, last updated 2012-12-04.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Why this study was terminated
See termination reason in detailed description.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
11 Years to 17 Years
Sex
All
01

Study summary

  • To assess the effect of a long-term treatment by Genotonorm on linear growth in children with short stature receiving steroid therapy
  • To assess the effect of a long term treatment with Genotonorm on bone mineralisation
  • To assess the effect of a long term treatment with Genotonorm on body composition
Read the detailed description

This trial terminated on 10-Jun-2011 due to prolonged issues with drug accountability and data collection discrepancies. The decision to terminate was not based on any safety concerns.

02

Conditions studied

  • Endocrine System Diseases
03

In context

Endocrine System Diseases

322 studies on the registry are indexed under Endocrine System Diseases; 51 are open to participants now.

This study's enrollment of 30 is below the median of 69 across 221 interventional studies indexed under Endocrine System Diseases.

Browse Endocrine System Diseases studies →

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 146 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
11 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children with juvenile arthritis or nephrotic syndrome
  • Before or during puberty

Exclusion criteria

Exclusion Criteria:

  • Diabetes Type 1 and 2
  • Endocrine disease, except well substituted hypothyroidism
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Somatropin

    Drug: Somatropin

Interventions

  • liquid, daily, until final height Dosage: 0,46 mg/kg/week . The maximum dose should not exceed 50 µg/Kg/day

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Height Standard Deviation Score According to Chronological Age (SDS/CA) at Year 3

    Height was measured using a wall mounted device (example, Harpenden stadiometer). Height SDS/CA was obtained by measuring the height, subtracting chronological age- and gender-appropriate mean height and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.

    Time frame: Baseline, Year 3

  2. Change From Baseline in Height Standard Deviation Score According to Chronological Age (SDS/CA) at Final Height

    Height was measured using a wall mounted device (example, Harpenden stadiometer). Height SDS/CA was obtained by measuring the height, subtracting chronological age- and gender-appropriate mean height and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.

    Time frame: Baseline, when final height was reached (assessed up to Year 11)

  3. Change From Baseline in Weight Standard Deviation Score (SDS) at Final Height

    Body weight was measured using a balance scale. Weight SDS was obtained by measuring the weight, subtracting age- and gender-appropriate mean weight and dividing the result by standard deviation of that mean (as obtained from age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.

    Time frame: Baseline, when final height was reached (assessed up to Year 11)

  4. Puberty Stage at Final Height

    Pubertal stage (graded from I to V for breast development and pubic hair development) according to the Tanner's method was collected. A low stage (Stage I) corresponds to a pre-pubertal stage and a high stage (Stage V) to an adult stage.

    Time frame: When final height was reached (assessed up to Year 11)

Secondary outcomes

  1. Bone Age

    Bone age was determined by the Greulich and Pyle method using left wrist and hand X-ray.

    Time frame: Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11

  2. Lean Body Mass

    Lean body mass, a measurement of body composition, was assessed by Dual Energy X-ray Absorptiometry (DEXA) scan.

    Time frame: Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11

  3. Annual Percent Change in Lean Body Mass at Year 1, 2 and 3

    Lean body mass, a measurement of body composition, was assessed by DEXA scan. Annual percent change: (Lean body mass at current year minus lean body mass at previous year) divided by lean body mass at previous year, multiplied by 100.

    Time frame: Baseline, Year 1, 2, 3

  4. Percent Change From Baseline in Lean Body Mass at Year 3

    Lean body mass, a measurement of body composition, was assessed by DEXA scan. Percent change: (Lean body mass at Year 3 minus lean body mass at baseline) divided by lean body mass at baseline, multiplied by 100.

    Time frame: Baseline, Year 3

  5. Lean Body Mass as Percentage of Total Weight

    Lean body mass, a measurement of body composition, was assessed by DEXA scan.

    Time frame: Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11

  6. Lean Body Mass Standard Deviation Score According to Chronological Age (SDS/CA)

    Lean body mass was assessed by DEXA scan. Lean body mass SDS/CA was obtained by measuring lean body mass, subtracting the chronological age- and gender-appropriate mean lean body mass and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.

    Time frame: Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11

  7. Fat Mass

    Fat mass, a measurement of body composition, was assessed by DEXA scan.

    Time frame: Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11

  8. Annual Percent Change in Fat Mass at Year 1, 2 and 3

    Fat mass, a measurement of body composition, was assessed by DEXA scan. Annual percent change: (Fat mass at current year minus fat mass at previous year) divided by fat mass at previous year, multiplied by 100.

    Time frame: Baseline, Year 1, 2, 3

  9. Percent Change From Baseline in Fat Mass at Year 3

    Fat mass, a measurement of body composition, was assessed by DEXA scan. Percent change: (Fat mass at Year 3 minus fat mass at baseline) divided by fat mass at baseline, multiplied by 100.

    Time frame: Baseline, Year 3

  10. Fat Mass as Percentage of Total Weight

    Fat mass, a measurement of body composition, was assessed by DEXA scan.

    Time frame: Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11

  11. Fat Mass Standard Deviation Score According to Chronological Age (SDS/CA)

    Fat mass was assessed by DEXA scan. Fat mass SDS/CA was obtained by measuring fat mass, subtracting chronological age- and gender-appropriate mean fat mass and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.

    Time frame: Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11

  12. Apparent Bone Mineral Density of Lumbar Spine (BMAD [LS])

    BMAD (LS) was assessed by DEXA scan.

    Time frame: Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11

  13. Apparent Bone Mineral Density Standard Deviation Score of Lumbar Spine According to Chronological Age (BMAD [LS] [SDS/CA])

    BMAD (LS) was assessed by DEXA scan. BMAD (LS) (SDS/CA) was obtained by measuring the BMAD (LS), subtracting chronological age- and gender-appropriate mean BMAD (LS) and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.

    Time frame: Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11

  14. Apparent Bone Mineral Density Standard Deviation Score of Lumber Spine According to Tanner Puberty Stage (BMAD [LS] [SDS/Tanner Puberty Stage])

    BMAD (LS) was assessed by DEXA scan. BMAD (LS) (SDS/Tanner Puberty Stage) was obtained by measuring BMAD (LS), subtracting Tanner puberty stage- and gender-appropriate mean BMAD (LS) and dividing the result by standard deviation of that mean (as obtained from Tanner puberty stage- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.

    Time frame: Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11

  15. Bone Mineral Density of Total Body (BMD [TB])

    BMD (TB) was assessed by DEXA scan.

    Time frame: Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11

  16. Bone Mineral Density of Lumbar Spine (BMD [LS])

    BMD (LS) was assessed by DEXA scan.

    Time frame: Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11

  17. Bone Mineral Content of Total Body (BMC [TB])

    DEXA scan of BMC was used to evaluate potential bone effects of treatment. BMC is an estimate of the amount of mineral (such as calcium) in the bone.

    Time frame: Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11

  18. Annual Percent Change in Bone Mineral Content of Total Body (BMC [TB]) at Year 1, 2 and 3

    BMC is an estimate of the amount of mineral (such as calcium) in the bone. Annual percent change: (BMC \[TB\] at current year minus BMC \[TB\] at previous year) divided by BMC \[TB\] at previous year, multiplied by 100.

    Time frame: Baseline, Year 1, 2, 3

  19. Percent Change From Baseline in Bone Mineral Content of Total Body (BMC [TB]) at Year 3

    BMC is an estimate of the amount of mineral (such as calcium) in the bone. Percent change: (BMC \[TB\] at Year 3 minus BMC \[TB\] at baseline) divided by BMC \[TB\] at baseline, multiplied by 100.

    Time frame: Baseline, Year 3

  20. Bone Mineral Content Standard Deviation Score of Total Body According to Chronological Age (BMC [TB] [SDS/CA])

    BMC (TB) was measured by DEXA scan. BMC (TB) (SDS/CA) was obtained by measuring BMC (TB), subtracting the chronological age- and gender-appropriate mean BMC (TB) and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.

    Time frame: Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11

  21. Bone Mineral Content Standard Deviation Score of Total Body According to Tanner Puberty Stage (BMC [TB] [SDS/Tanner Puberty Stage])

    BMC (TB) was measured by DEXA scan. BMC (TB) (SDS/Tanner Puberty Stage) was obtained by measuring BMC (TB), subtracting the Tanner puberty stage- and gender-appropriate mean BMC (TB) and dividing the result by standard deviation of that mean (as obtained from Tanner puberty stage- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.

    Time frame: Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11

Other outcomes

  1. Growth Velocity (GV)

    Growth velocity measures the annual rate of increase in height.

    Time frame: Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11

  2. Growth Velocity Standard Deviation Score According to Chronological Age (GV [SDS/CA])

    GV measures the annual rate of increase in height. GV (SDS/CA) was obtained by measuring GV, subtracting the chronological age- and gender-appropriate mean GV and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.

    Time frame: Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11

  3. Growth Velocity Standard Deviation Score According to Bone Age (GV [SDS/BA])

    GV measures the annual rate of increase in height. GV (SDS/BA) was obtained by measuring GV, subtracting the bone age- and gender-appropriate mean GV and dividing the result by standard deviation of that mean (as obtained from bone age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.

    Time frame: Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11

  4. Insulin-like Growth Factor-1 (IGF-1) Concentration up to Year 3

    Time frame: Baseline, Year 1, 2, 3

  5. Insulin-like Growth Factor-1 (IGF-1) Concentration After Year 3

    Time frame: Year 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10; 0.5 and 1 year after somatropin discontinuation, Final Height (assessed up to Year 11)

07

Results

Posted Dec 4, 2012
Limitations and caveats
Results for secondary and other pre-specified endpoints (except IGF-1) are reported for only up to 3 years because data beyond Year 3 was not summarized as the study was terminated due to Good Clinical Practice (GCP) non-compliance issues.

Participant flow

Period 1 (up to 3 Years)
Participant flow — Period 1 (up to 3 Years)
MilestoneSomatropin- Up To Year 3 (Juvenile Idiopathic Arthritis)Somatropin- Up To Year 3 (Nephrotic Syndrome)Somatropin- After Year 3
Started15150
Completed15110
Not completed040
Withdrew: Serious adverse event010
Withdrew: Non compliance010
Withdrew: Withdrawal by subject010
Withdrew: Other010
Between Period 1 and Period 2
Participant flow — Between Period 1 and Period 2
MilestoneSomatropin- Up To Year 3 (Juvenile Idiopathic Arthritis)Somatropin- Up To Year 3 (Nephrotic Syndrome)Somatropin- After Year 3
Started0026
Consented0024
Completed0021
Not completed005
Withdrew: Did not consent to continue treatment002
Withdrew: Consented, not assigned to treatment003
Period 2 (After 3 Years)
Participant flow — Period 2 (After 3 Years)
MilestoneSomatropin- Up To Year 3 (Juvenile Idiopathic Arthritis)Somatropin- Up To Year 3 (Nephrotic Syndrome)Somatropin- After Year 3
Started0021
Completed0013
Not completed008
Withdrew: Lost to follow-up002
Withdrew: Withdrawal by subject001
Withdrew: Other005

Outcome measures

PrimaryChange From Baseline in Height Standard Deviation Score According to Chronological Age (SDS/CA) at Year 3

Height was measured using a wall mounted device (example, Harpenden stadiometer). Height SDS/CA was obtained by measuring the height, subtracting chronological age- and gender-appropriate mean height and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.

Time frame:
Baseline, Year 3
Reported as:
Median · Standard Deviation Score (SDS)
Change From Baseline in Height Standard Deviation Score According to Chronological Age (SDS/CA) at Year 3
Standard Deviation Score (SDS)Somatropin- Up To Year 3 (Juvenile Idiopathic Arthritis)Somatropin- Up To Year 3 (Nephrotic Syndrome)
Baseline-3.6 (-5.1 to -2.3)-2.5 (-2.8 to -2.2)
Change at Year 30.2 (-1.5 to 1.8)1.1 (0.8 to 1.5)
PrimaryChange From Baseline in Height Standard Deviation Score According to Chronological Age (SDS/CA) at Final Height

Height was measured using a wall mounted device (example, Harpenden stadiometer). Height SDS/CA was obtained by measuring the height, subtracting chronological age- and gender-appropriate mean height and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.

Time frame:
Baseline, when final height was reached (assessed up to Year 11)
Reported as:
Median · SDS
Change From Baseline in Height Standard Deviation Score According to Chronological Age (SDS/CA) at Final Height
SDSSomatropin- After Year 3
Baseline (n = 21)-2.86 (-5.61 to -1.00)
Change at Final Height (n = 4)0.71 (0.27 to 3.08)
PrimaryChange From Baseline in Weight Standard Deviation Score (SDS) at Final Height

Body weight was measured using a balance scale. Weight SDS was obtained by measuring the weight, subtracting age- and gender-appropriate mean weight and dividing the result by standard deviation of that mean (as obtained from age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.

Time frame:
Baseline, when final height was reached (assessed up to Year 11)
Reported as:
Median · SDS
Change From Baseline in Weight Standard Deviation Score (SDS) at Final Height
SDSSomatropin- After Year 3
Baseline (n = 21)-1.53 (-4.77 to 2.64)
Change at Final Height (n = 4)-0.43 (-1.37 to 1.09)
PrimaryPuberty Stage at Final Height

Pubertal stage (graded from I to V for breast development and pubic hair development) according to the Tanner's method was collected. A low stage (Stage I) corresponds to a pre-pubertal stage and a high stage (Stage V) to an adult stage.

Time frame:
When final height was reached (assessed up to Year 11)
Reported as:
Number · participants
Puberty Stage at Final Height
participantsSomatropin- After Year 3
Pubic hair: Stage I (n=4)0
Pubic hair: Stage II (n=4)0
Pubic hair: Stage III (n=4)0
Pubic hair: Stage IV (n=4)0
Pubic hair: Stage V (n=4)4
Breast development: Stage I (n=1)0
Breast development: Stage II (n=1)0
Breast development: Stage III (n=1)0
Breast development: Stage IV (n=1)0
Breast development: Stage V (n=1)1
SecondaryBone Age

Bone age was determined by the Greulich and Pyle method using left wrist and hand X-ray.

Time frame:
Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Reported as:
Median · years
Bone Age
yearsSomatropin- Up To Year 3 (Juvenile Idiopathic Arthritis)Somatropin- Up To Year 3 (Nephrotic Syndrome)
Baseline (n = 14, 15)8.9 (7.0 to 10.0)10.5 (7.0 to 13.0)
Year 1 (n = 14, 15)9.5 (7.8 to 11.5)11.5 (7.0 to 14.0)
Year 2 (n = 15, 13)10.0 (8.0 to 13.0)14.0 (10.0 to 14.5)
Year 3 (n = 15, 14)11.3 (8.8 to 14.5)14.0 (11.5 to 15.0)
SecondaryLean Body Mass

Lean body mass, a measurement of body composition, was assessed by Dual Energy X-ray Absorptiometry (DEXA) scan.

Time frame:
Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Reported as:
Median · kilogram (kg)
Lean Body Mass
kilogram (kg)Somatropin- Up To Year 3 (Juvenile Idiopathic Arthritis)Somatropin- Up To Year 3 (Nephrotic Syndrome)
Baseline (n = 15, 15)17.69 (14.96 to 19.96)23.56 (16.77 to 32.43)
Year 1 (n = 15, 13)19.77 (16.62 to 24.58)31.16 (20.77 to 39.10)
Year 2 (n = 14, 12)21.20 (18.79 to 25.13)34.14 (25.30 to 46.30)
Year 3 (n = 14, 11)23.21 (20.88 to 25.55)36.38 (26.49 to 42.76)
SecondaryAnnual Percent Change in Lean Body Mass at Year 1, 2 and 3

Lean body mass, a measurement of body composition, was assessed by DEXA scan. Annual percent change: (Lean body mass at current year minus lean body mass at previous year) divided by lean body mass at previous year, multiplied by 100.

Time frame:
Baseline, Year 1, 2, 3
Reported as:
Median · percent change
Annual Percent Change in Lean Body Mass at Year 1, 2 and 3
percent changeSomatropin- Up To Year 3 (Juvenile Idiopathic Arthritis)Somatropin- Up To Year 3 (Nephrotic Syndrome)
Annual Change at Year 1 (n = 15, 13)18.95 (10.04 to 21.83)22.97 (17.54 to 28.80)
Annual Change at Year 2 (n = 14, 11)7.75 (1.31 to 12.16)7.33 (4.76 to 18.91)
Annual Change at Year 3 (n = 13, 9)9.83 (2.67 to 13.33)7.90 (1.88 to 15.08)
SecondaryPercent Change From Baseline in Lean Body Mass at Year 3

Lean body mass, a measurement of body composition, was assessed by DEXA scan. Percent change: (Lean body mass at Year 3 minus lean body mass at baseline) divided by lean body mass at baseline, multiplied by 100.

Time frame:
Baseline, Year 3
Reported as:
Median · percent change
Percent Change From Baseline in Lean Body Mass at Year 3
percent changeSomatropin- Up To Year 3 (Juvenile Idiopathic Arthritis)Somatropin- Up To Year 3 (Nephrotic Syndrome)
Percent Change From Baseline in Lean Body Mass at Year 336.82 (22.45 to 52.39)54.44 (43.06 to 62.30)
SecondaryLean Body Mass as Percentage of Total Weight

Lean body mass, a measurement of body composition, was assessed by DEXA scan.

Time frame:
Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Reported as:
Median · percentage of total weight
Lean Body Mass as Percentage of Total Weight
percentage of total weightSomatropin- Up To Year 3 (Juvenile Idiopathic Arthritis)Somatropin- Up To Year 3 (Nephrotic Syndrome)
Baseline (n = 15, 15)70.56 (58.25 to 80.10)60.69 (55.29 to 69.14)
Year 1 (n = 15, 13)76.57 (64.16 to 83.89)65.97 (59.58 to 76.19)
Year 2 (n = 14, 12)73.32 (63.85 to 80.96)69.95 (59.55 to 80.07)
Year 3 (n = 14, 11)72.94 (66.79 to 78.21)67.24 (59.83 to 74.37)
SecondaryLean Body Mass Standard Deviation Score According to Chronological Age (SDS/CA)

Lean body mass was assessed by DEXA scan. Lean body mass SDS/CA was obtained by measuring lean body mass, subtracting the chronological age- and gender-appropriate mean lean body mass and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.

Time frame:
Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Reported as:
Median · SDS
Lean Body Mass Standard Deviation Score According to Chronological Age (SDS/CA)
SDSSomatropin- Up To Year 3 (Juvenile Idiopathic Arthritis)Somatropin- Up To Year 3 (Nephrotic Syndrome)
Baseline (n = 15, 15)-1.50 (-1.81 to -0.94)-0.90 (-1.40 to -0.54)
Year 1 (n = 15, 13)-1.13 (-1.64 to -0.67)-0.52 (-0.97 to 0.20)
Year 2 (n = 14, 12)-1.26 (-1.94 to -0.78)-0.87 (-1.40 to -0.32)
Year 3 (n = 13, 11)-1.75 (-1.96 to -0.94)-1.29 (-2.36 to -0.14)
SecondaryFat Mass

Fat mass, a measurement of body composition, was assessed by DEXA scan.

Time frame:
Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Reported as:
Median · kg
Fat Mass
kgSomatropin- Up To Year 3 (Juvenile Idiopathic Arthritis)Somatropin- Up To Year 3 (Nephrotic Syndrome)
Baseline (n = 15, 15)5.47 (4.04 to 11.34)13.62 (9.51 to 18.05)
Year 1 (n = 15, 13)4.81 (2.64 to 10.21)10.99 (7.22 to 18.97)
Year 2 (n = 14, 12)6.97 (3.12 to 11.48)16.70 (5.99 to 20.59)
Year 3 (n = 14, 11)6.90 (4.94 to 11.33)15.19 (10.28 to 22.87)
SecondaryAnnual Percent Change in Fat Mass at Year 1, 2 and 3

Fat mass, a measurement of body composition, was assessed by DEXA scan. Annual percent change: (Fat mass at current year minus fat mass at previous year) divided by fat mass at previous year, multiplied by 100.

Time frame:
Baseline, Year 1, 2, 3
Reported as:
Median · percent change
Annual Percent Change in Fat Mass at Year 1, 2 and 3
percent changeSomatropin- Up To Year 3 (Juvenile Idiopathic Arthritis)Somatropin- Up To Year 3 (Nephrotic Syndrome)
Annual Change at Year 1 (n = 15, 13)-11.21 (-24.18 to 27.46)-3.71 (-19.44 to 15.73)
Annual Change at Year 2 (n = 14, 11)29.52 (4.97 to 34.56)-1.05 (-20.82 to 79.15)
Annual Change at Year 3 (n = 13, 9)26.61 (-4.54 to 52.90)19.37 (10.60 to 40.12)
SecondaryPercent Change From Baseline in Fat Mass at Year 3

Fat mass, a measurement of body composition, was assessed by DEXA scan. Percent change: (Fat mass at Year 3 minus fat mass at baseline) divided by fat mass at baseline, multiplied by 100.

Time frame:
Baseline, Year 3
Reported as:
Median · percent change
Percent Change From Baseline in Fat Mass at Year 3
percent changeSomatropin- Up To Year 3 (Juvenile Idiopathic Arthritis)Somatropin- Up To Year 3 (Nephrotic Syndrome)
Percent Change From Baseline in Fat Mass at Year 319.46 (3.83 to 73.79)37.56 (8.18 to 44.15)
SecondaryFat Mass as Percentage of Total Weight

Fat mass, a measurement of body composition, was assessed by DEXA scan.

Time frame:
Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Reported as:
Median · percentage of total weight
Fat Mass as Percentage of Total Weight
percentage of total weightSomatropin- Up To Year 3 (Juvenile Idiopathic Arthritis)Somatropin- Up To Year 3 (Nephrotic Syndrome)
Baseline (n = 15, 15)25.0 (13.7 to 35.8)33.8 (29.5 to 37.2)
Year 1 (n = 15, 13)17.4 (12.3 to 31.4)30.0 (21.9 to 34.7)
Year 2 (n = 14, 12)21.1 (14.2 to 32.4)27.1 (15.0 to 36.2)
Year 3 (n = 14, 11)21.3 (17.1 to 28.6)26.4 (19.1 to 37.6)
SecondaryFat Mass Standard Deviation Score According to Chronological Age (SDS/CA)

Fat mass was assessed by DEXA scan. Fat mass SDS/CA was obtained by measuring fat mass, subtracting chronological age- and gender-appropriate mean fat mass and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.

Time frame:
Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Reported as:
Median · SDS
Fat Mass Standard Deviation Score According to Chronological Age (SDS/CA)
SDSSomatropin- Up To Year 3 (Juvenile Idiopathic Arthritis)Somatropin- Up To Year 3 (Nephrotic Syndrome)
Baseline (n = 15, 15)1.51 (0.50 to 2.22)2.20 (1.95 to 2.39)
Year 1 (n = 15, 13)0.80 (-0.33 to 1.64)1.98 (0.88 to 2.23)
Year 2 (n = 14, 12)0.86 (-0.15 to 1.66)1.79 (0.55 to 2.33)
Year 3 (n = 13, 11)1.27 (0.25 to 1.55)1.74 (0.90 to 2.41)
SecondaryApparent Bone Mineral Density of Lumbar Spine (BMAD [LS])

BMAD (LS) was assessed by DEXA scan.

Time frame:
Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Reported as:
Median · gram per cubic centimeter (g/cm^3)
Apparent Bone Mineral Density of Lumbar Spine (BMAD [LS])
gram per cubic centimeter (g/cm^3)Somatropin- Up To Year 3 (Juvenile Idiopathic Arthritis)Somatropin- Up To Year 3 (Nephrotic Syndrome)
Baseline (n = 15, 14)0.184 (0.168 to 0.242)0.223 (0.211 to 0.241)
Year 1 (n = 14, 13)0.209 (0.163 to 0.243)0.237 (0.201 to 0.244)
Year 2 (n = 15, 14)0.215 (0.181 to 0.248)0.249 (0.217 to 0.266)
Year 3 (n = 13, 12)0.239 (0.205 to 0.254)0.242 (0.223 to 0.266)
SecondaryApparent Bone Mineral Density Standard Deviation Score of Lumbar Spine According to Chronological Age (BMAD [LS] [SDS/CA])

BMAD (LS) was assessed by DEXA scan. BMAD (LS) (SDS/CA) was obtained by measuring the BMAD (LS), subtracting chronological age- and gender-appropriate mean BMAD (LS) and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.

Time frame:
Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Reported as:
Median · SDS
Apparent Bone Mineral Density Standard Deviation Score of Lumbar Spine According to Chronological Age (BMAD [LS] [SDS/CA])
SDSSomatropin- Up To Year 3 (Juvenile Idiopathic Arthritis)Somatropin- Up To Year 3 (Nephrotic Syndrome)
Baseline (n = 15, 14)-3.21 (-4.02 to -1.26)-1.53 (-1.94 to -1.35)
Year 1 (n = 14, 13)-2.66 (-3.70 to -1.07)-1.51 (-2.32 to -0.95)
Year 2 (n = 15, 14)-2.55 (-3.74 to -0.95)-1.42 (-1.86 to -0.72)
Year 3 (n 12, 12)-1.77 (-2.43 to -1.21)-1.63 (-2.43 to -0.74)
SecondaryApparent Bone Mineral Density Standard Deviation Score of Lumber Spine According to Tanner Puberty Stage (BMAD [LS] [SDS/Tanner Puberty Stage])

BMAD (LS) was assessed by DEXA scan. BMAD (LS) (SDS/Tanner Puberty Stage) was obtained by measuring BMAD (LS), subtracting Tanner puberty stage- and gender-appropriate mean BMAD (LS) and dividing the result by standard deviation of that mean (as obtained from Tanner puberty stage- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.

Time frame:
Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Reported as:
Median · SDS
Apparent Bone Mineral Density Standard Deviation Score of Lumber Spine According to Tanner Puberty Stage (BMAD [LS] [SDS/Tanner Puberty Stage])
SDSSomatropin- Up To Year 3 (Juvenile Idiopathic Arthritis)Somatropin- Up To Year 3 (Nephrotic Syndrome)
Baseline (n = 8, 8)-4.27 (-5.47 to -2.38)-3.09 (-3.36 to -2.31)
Year 1 (n = 10, 7)-3.70 (-4.80 to -2.48)-3.23 (-4.64 to -1.74)
Year 2 (n = 10, 9)-4.11 (-4.36 to -1.72)-2.60 (-3.04 to -2.17)
Year 3 (n = 10, 8)-3.04 (-4.06 to -2.27)-2.96 (-3.37 to -2.76)
SecondaryBone Mineral Density of Total Body (BMD [TB])

BMD (TB) was assessed by DEXA scan.

Time frame:
Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Reported as:
Median · gram per square centimeter (g/cm^2)
Bone Mineral Density of Total Body (BMD [TB])
gram per square centimeter (g/cm^2)Somatropin- Up To Year 3 (Juvenile Idiopathic Arthritis)Somatropin- Up To Year 3 (Nephrotic Syndrome)
Baseline (n = 15, 15)0.78 (0.76 to 0.86)0.90 (0.81 to 1.00)
Year 1 (n = 15, 14)0.80 (0.76 to 0.87)0.92 (0.85 to 1.02)
Year 2 (n = 14, 11)0.81 (0.77 to 0.89)0.96 (0.86 to 1.09)
Year 3 (n = 13, 11)0.84 (0.80 to 0.91)0.99 (0.89 to 1.08)
SecondaryBone Mineral Density of Lumbar Spine (BMD [LS])

BMD (LS) was assessed by DEXA scan.

Time frame:
Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Reported as:
Median · g/cm^2
Bone Mineral Density of Lumbar Spine (BMD [LS])
g/cm^2Somatropin- Up To Year 3 (Juvenile Idiopathic Arthritis)Somatropin- Up To Year 3 (Nephrotic Syndrome)
Baseline (n = 15, 15)0.55 (0.47 to 0.64)0.72 (0.67 to 0.85)
Year 1 (n = 14, 14)0.61 (0.48 to 0.74)0.76 (0.66 to 0.91)
Year 2 (n = 15, 14)0.64 (0.56 to 0.84)0.85 (0.77 to 1.04)
Year 3 (n = 13, 12)0.74 (0.60 to 0.85)0.93 (0.79 to 1.07)
SecondaryBone Mineral Content of Total Body (BMC [TB])

DEXA scan of BMC was used to evaluate potential bone effects of treatment. BMC is an estimate of the amount of mineral (such as calcium) in the bone.

Time frame:
Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Reported as:
Median · gram
Bone Mineral Content of Total Body (BMC [TB])
gramSomatropin- Up To Year 3 (Juvenile Idiopathic Arthritis)Somatropin- Up To Year 3 (Nephrotic Syndrome)
Baseline (n = 15, 15)636.36 (498.47 to 939.71)1233.58 (772.41 to 1650.08)
Year 1 (n = 15, 14)775.46 (578.97 to 1119.60)1576.15 (939.71 to 1739.38)
Year 2 (n = 14, 11)855.70 (690.07 to 1059.67)2003.49 (1070.42 to 2243.61)
Year 3 (n = 13, 11)1112.78 (807.30 to 1176.70)1997.74 (1296.00 to 2195.17)
SecondaryAnnual Percent Change in Bone Mineral Content of Total Body (BMC [TB]) at Year 1, 2 and 3

BMC is an estimate of the amount of mineral (such as calcium) in the bone. Annual percent change: (BMC \[TB\] at current year minus BMC \[TB\] at previous year) divided by BMC \[TB\] at previous year, multiplied by 100.

Time frame:
Baseline, Year 1, 2, 3
Reported as:
Median · percent change
Annual Percent Change in Bone Mineral Content of Total Body (BMC [TB]) at Year 1, 2 and 3
percent changeSomatropin- Up To Year 3 (Juvenile Idiopathic Arthritis)Somatropin- Up To Year 3 (Nephrotic Syndrome)
Year 1 (n = 15, 14)12.51 (7.66 to 21.86)20.16 (11.74 to 23.05)
Year 2 (n = 14, 11)17.47 (12.20 to 19.93)13.91 (10.63 to 18.93)
Year 3 (n = 12, 9)12.03 (4.50 to 14.54)7.39 (7.29 to 13.30)
SecondaryPercent Change From Baseline in Bone Mineral Content of Total Body (BMC [TB]) at Year 3

BMC is an estimate of the amount of mineral (such as calcium) in the bone. Percent change: (BMC \[TB\] at Year 3 minus BMC \[TB\] at baseline) divided by BMC \[TB\] at baseline, multiplied by 100.

Time frame:
Baseline, Year 3
Reported as:
Median · percent change
Percent Change From Baseline in Bone Mineral Content of Total Body (BMC [TB]) at Year 3
percent changeSomatropin- Up To Year 3 (Juvenile Idiopathic Arthritis)Somatropin- Up To Year 3 (Nephrotic Syndrome)
Percent Change From Baseline in Bone Mineral Content of Total Body (BMC [TB]) at Year 346.63 (24.94 to 73.91)60.56 (36.49 to 67.79)
SecondaryBone Mineral Content Standard Deviation Score of Total Body According to Chronological Age (BMC [TB] [SDS/CA])

BMC (TB) was measured by DEXA scan. BMC (TB) (SDS/CA) was obtained by measuring BMC (TB), subtracting the chronological age- and gender-appropriate mean BMC (TB) and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.

Time frame:
Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Reported as:
Median · SDS
Bone Mineral Content Standard Deviation Score of Total Body According to Chronological Age (BMC [TB] [SDS/CA])
SDSSomatropin- Up To Year 3 (Juvenile Idiopathic Arthritis)Somatropin- Up To Year 3 (Nephrotic Syndrome)
Baseline (n = 15, 15)-1.95 (-2.60 to -1.03)-0.42 (-1.23 to 0.19)
Year 1 (n = 15, 14)-1.85 (-2.43 to -0.73)-0.19 (-1.13 to 0.37)
Year 2 (n = 14, 11)-1.66 (-2.27 to -1.14)-0.37 (-1.24 to 0.43)
Year 3 (n = 12, 11)-1.65 (-2.22 to -0.35)-0.09 (-0.72 to 0.60)
SecondaryBone Mineral Content Standard Deviation Score of Total Body According to Tanner Puberty Stage (BMC [TB] [SDS/Tanner Puberty Stage])

BMC (TB) was measured by DEXA scan. BMC (TB) (SDS/Tanner Puberty Stage) was obtained by measuring BMC (TB), subtracting the Tanner puberty stage- and gender-appropriate mean BMC (TB) and dividing the result by standard deviation of that mean (as obtained from Tanner puberty stage- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.

Time frame:
Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Reported as:
Median · SDS
Bone Mineral Content Standard Deviation Score of Total Body According to Tanner Puberty Stage (BMC [TB] [SDS/Tanner Puberty Stage])
SDSSomatropin- Up To Year 3 (Juvenile Idiopathic Arthritis)Somatropin- Up To Year 3 (Nephrotic Syndrome)
Baseline (n = 8, 8)-2.19 (-2.47 to -0.96)1.41 (-0.39 to 2.46)
Year 1 (n = 10, 8)-1.56 (-2.24 to -0.92)-0.52 (-1.53 to 1.65)
Year 2 (n = 9, 7)-2.38 (-2.72 to -1.14)-0.47 (-1.53 to 0.37)
Year 3 (n = 9, 7)-2.38 (-2.56 to -1.28)-0.17 (-1.22 to 0.83)
Other pre-specifiedGrowth Velocity (GV)

Growth velocity measures the annual rate of increase in height.

Time frame:
Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Reported as:
Median · cm/year
Growth Velocity (GV)
cm/yearSomatropin- Up To Year 3 (Juvenile Idiopathic Arthritis)Somatropin- Up To Year 3 (Nephrotic Syndrome)
Baseline (n = 11, 14)2.9 (1.1 to 4.8)3.8 (2.7 to 4.4)
Year 1 (n = 14, 15)6.5 (3.5 to 8.6)8.3 (5.4 to 8.7)
Year 2 (n = 14, 15)5.3 (1.8 to 6.9)7.0 (4.1 to 9.2)
Year 3 (n = 14, 14)4.5 (1.9 to 6.8)5.9 (2.3 to 7.2)
Other pre-specifiedGrowth Velocity Standard Deviation Score According to Chronological Age (GV [SDS/CA])

GV measures the annual rate of increase in height. GV (SDS/CA) was obtained by measuring GV, subtracting the chronological age- and gender-appropriate mean GV and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.

Time frame:
Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Reported as:
Median · SDS
Growth Velocity Standard Deviation Score According to Chronological Age (GV [SDS/CA])
SDSSomatropin- Up To Year 3 (Juvenile Idiopathic Arthritis)Somatropin- Up To Year 3 (Nephrotic Syndrome)
Baseline (n = 10, 14)-1.7 (-2.8 to -1.3)-2.2 (-2.9 to -1.3)
Year 1 (n = 14, 15)1.0 (-1.5 to 3.9)1.3 (-0.7 to 1.9)
Year 2 (n = 14, 15)0.1 (-1.9 to 3.7)2.9 (1.4 to 4.2)
Year 3 (n = 14, 14)0.4 (-0.5 to 2.1)2.9 (-0.1 to 5.7)
Other pre-specifiedGrowth Velocity Standard Deviation Score According to Bone Age (GV [SDS/BA])

GV measures the annual rate of increase in height. GV (SDS/BA) was obtained by measuring GV, subtracting the bone age- and gender-appropriate mean GV and dividing the result by standard deviation of that mean (as obtained from bone age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.

Time frame:
Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Reported as:
Median · SDS
Growth Velocity Standard Deviation Score According to Bone Age (GV [SDS/BA])
SDSSomatropin- Up To Year 3 (Juvenile Idiopathic Arthritis)Somatropin- Up To Year 3 (Nephrotic Syndrome)
Baseline (n = 9, 14)-2.8 (-3.9 to -1.7)-2.1 (-2.4 to -1.1)
Year 1 (n = 13, 15)0.8 (-0.9 to 2.9)0.6 (-0.6 to 2.4)
Year 2 (n = 14, 13)-0.3 (-3.9 to 1.1)1.4 (-0.6 to 2.0)
Year 3 (n = 14, 14)-0.9 (-2.2 to 0.9)0.1 (-1.7 to 3.4)
Other pre-specifiedInsulin-like Growth Factor-1 (IGF-1) Concentration up to Year 3
Time frame:
Baseline, Year 1, 2, 3
Reported as:
Median · nanogram per milliliter (ng/mL)
Insulin-like Growth Factor-1 (IGF-1) Concentration up to Year 3
nanogram per milliliter (ng/mL)Somatropin- Up To Year 3 (Juvenile Idiopathic Arthritis)Somatropin- Up To Year 3 (Nephrotic Syndrome)
Baseline (n = 15, 12)157.0 (61.0 to 345.0)344.5 (191.0 to 719.0)
Year 1 (n = 15, 15)400.0 (154.0 to 1370)952.0 (424.0 to 1658.0)
Year 2 (n = 15, 14)388.0 (188.0 to 1338.0)880.0 (311.0 to 1718.0)
Year 3 (n = 15, 14)405.0 (239.0 to 1160.0)657.0 (323.0 to 1298.0)
Other pre-specifiedInsulin-like Growth Factor-1 (IGF-1) Concentration After Year 3
Time frame:
Year 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10; 0.5 and 1 year after somatropin discontinuation, Final Height (assessed up to Year 11)
Reported as:
Median · milligram per deciliter (mg/dL)
Insulin-like Growth Factor-1 (IGF-1) Concentration After Year 3
milligram per deciliter (mg/dL)Somatropin- After Year 3
Year 3.5 (n = 8)0.05 (0.04 to 0.09)
Year 4 (n = 19)0.06 (0.03 to 0.10)
Year 4.5 (n = 16)0.06 (0.02 to 0.14)
Year 5 (n = 17)0.05 (0.02 to 0.09)
Year 5.5 (n = 11)0.06 (0.02 to 0.09)
Year 6 (n = 14)0.05 (0.02 to 0.08)
Year 6.5 (n = 8)0.07 (0.02 to 0.09)
Year 7 (n = 8)0.06 (0.02 to 0.07)
Year 7.5 (n = 4)0.05 (0.03 to 0.07)
Year 8 (n = 6)0.06 (0.03 to 0.07)
Year 8.5 (n = 2)0.08 (0.07 to 0.08)
Year 9 (n = 2)0.06 (0.06 to 0.07)
Year 9.5 (n = 1)0.07 (0.07 to 0.07)
Year 10 (n = 1)0.05 (0.05 to 0.05)
0.5 years after somatropin discontinuation (n = 2)0.03 (0.03 to 0.04)
1 year after somatropin discontinuation (n = 2)0.03 (0.02 to 0.05)
Final height (n = 3)0.06 (0.05 to 0.07)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Somatropin- Up To Year 3 (Juvenile Idiopathic Arthritis)—13/15 (86.7%)13/15 (86.7%)
Somatropin- Up To Year 3 (Nephrotic Syndrome)—14/15 (93.3%)14/15 (93.3%)
Somatropin- After Year 3—19/21 (90.5%)21/21 (100%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventSomatropin- Up To Year 3 (Juvenile Idiopathic Arthritis)Somatropin- Up To Year 3 (Nephrotic Syndrome)Somatropin- After Year 3
Nephrotic syndromeRenal and urinary disorders0/159/154/21
Juvenile arthritisMusculoskeletal and connective tissue disorders2/150/156/21
Condition aggravatedGeneral disorders3/152/150/21
Rheumatoid arthritisMusculoskeletal and connective tissue disorders3/150/151/21
Abdominal painGastrointestinal disorders2/151/154/21
Hip arthroplastySurgical and medical procedures0/150/153/21
Diabetes mellitusMetabolism and nutrition disorders1/152/152/21
GastroenteritisInfections and infestations2/151/152/21
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/152/150/21
Biopsy kidneyInvestigations0/151/152/21
Most frequent other events
Showing 10 of 87
Most frequent other events
EventSomatropin- Up To Year 3 (Juvenile Idiopathic Arthritis)Somatropin- Up To Year 3 (Nephrotic Syndrome)Somatropin- After Year 3
Nephrotic syndromeRenal and urinary disorders0/1511/157/21
ProteinuriaRenal and urinary disorders0/156/153/21
Red blood cell sedimentation rate increasedInvestigations5/150/154/21
Joint effusionMusculoskeletal and connective tissue disorders4/150/154/21
Juvenile arthritisMusculoskeletal and connective tissue disorders3/150/155/21
Ear infectionInfections and infestations0/153/152/21
NasopharyngitisInfections and infestations0/153/152/21
RhinitisInfections and infestations0/153/152/21
Insulin-like growth factor increasedInvestigations0/153/153/21
HypertriglyceridaemiaMetabolism and nutrition disorders0/153/151/21

Baseline characteristics

Age Continuous
Age Continuous(years)Somatropin- Up To Year 3 (Juvenile Idiopathic Arthritis)Somatropin- Up To Year 3 (Nephrotic Syndrome)Total
Mean11.14 ± 3.3211.96 ± 3.8011.55 ± 3.53
Sex: Female, Male
Sex: Female, Male(Participants)Somatropin- Up To Year 3 (Juvenile Idiopathic Arthritis)Somatropin- Up To Year 3 (Nephrotic Syndrome)Total
Female9211
Male61319
08

Study locations

2 sites
  • Pfizer Investigational Site
    Paris, 75019, France
  • Pfizer Investigational Site
    Paris, 75743, France
09

References and documents

Publications

  • David H, Aupiais C, Louveau B, Quartier P, Jacqz-Aigrain E, Carel JC, Simon D. Growth Outcomes After GH Therapy of Patients Given Long-Term Corticosteroids for Juvenile Idiopathic Arthritis. J Clin Endocrinol Metab. 2017 Dec 1;102(12):4578-4587. doi: 10.1210/jc.2017-01455. PubMed 29029101 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2000, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2012, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2005
First posted
Sep 15, 2005
Start
Sep 2000
Primary completionActual
Sep 2011
CompletionActual
Sep 2011
Results first posted
Dec 4, 2012
Last update
Dec 4, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00174187
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 15, 2005
Start date
Sep 2000
Primary completion
Sep 2011
Completion
Sep 2011
Results posted
Dec 4, 2012
Last update
Dec 4, 2012

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion